Table 1 Demographic data of study subjects
From: Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis
| Healthy control subjects (n = 14) | Individuals with RA risk (n = 23) | Patients with RA (n = 24) | |
|---|---|---|---|
| Female sex, n (%) | 9 (64) | 20 (87) | 17 (70) |
| Median age, years, (IQR) | 29 (26–37) | 49 (35–57) | 56 (44–61) |
| IgM-RF-positive, n (%) | 0 (0) | 10 (43) | 20 (3–107) |
| IgM-RF level, kU/L, median (IQR) | – | 20 (3–107) | 131 (31–309) |
| ACPA-positive, n (%) | 0 (0) | 13 (57) | 18 (75) |
| Median ACPA level, kAU/L (IQR) | – | 43 (4–177) | 115 (21–924) |
| IgM-RF and ACPA both positive, n (%) | 0 (0) | 0 (0) | 14 (58) |
| Median DAS28, (IQR) | – | – | 5 (1–10)c |
| Median ESR, mm/h (IQR) | – | 7 (2–10) | 11 (5–27)b |
| Median CRP, mg/L (IQR) | 0.5 (0.3–1.2)c | 1.6 (0.9–3.2) | 4.6 (1.4–13)d |
| Median TJC68 (IQR) | 0 (0) | 1.5 (0–4.5) | 9 (4–20)e |
| Median SJC68 (IQR) | 0 (0) | 0 (0) | 5 (1–10)d |
| Treatment, n (%) | 9 (39) | ||
| Corticosteroids | 6 (26) | ||
| NSAIDs | 4 (17)f | ||
| DMARDs | 5 (22) | ||
| Failed TNF inhibitor therapy | 5 (22) |
